TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23431958

Group type: EXPERIMENTAL
Intervention: Oral ivermectin 200 µg/kg body weight
Number of subjects: 320

Group type: COMPARATOR
Intervention: Crotamiton 10% cream applied twice daily for five consecutive days
Number of subjects: 320
Study: 22516832

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 254

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254
Study: 20472503

Group type: EXPERIMENTAL
Intervention: recHCG (250 microg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: uHCG (10,000 IU)
Number of subjects: 30
Study: 18042502

Group type: EXPERIMENTAL
Intervention: fosamprenavir (FPV) with ritonavir (FPV/r)
Number of subjects: 700
Study: 16220584

Group type: EXPERIMENTAL
Intervention: Total Abdominal Hysterectomy (TAH)
Number of subjects: 319

Group type: COMPARATOR
Intervention: Subtotal Abdominal Hysterectomy (SAH)
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Both TAH and SAH
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Incontinent women
Number of subjects: 319
Study: 12116072

Group type: EXPERIMENTAL
Intervention: Multi-component behavioral intervention (educational intervention)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 272
Study: 12577414

Group type: EXPERIMENTAL
Intervention: RT-GSP (Radiotherapy combined with Ginseng polysaccharide injection)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Conventional therapy (Control group)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: RT-GSP
Number of subjects: 131
Study: 9442148

Group type: EXPERIMENTAL
Intervention: Iodixanol (nonionic dimer)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Iopromide (nonionic monomer)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Iodixanol
Number of subjects: 64
Study: 8156571

Group type: EXPERIMENTAL
Intervention: Coronary endarterectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional surgery using only bypasses
Number of subjects: 0
Study: 3063783

Group type: EXPERIMENTAL
Intervention: Active treatment (diazide‐hydrochlorothiazide with triamterene +/‐ methyldopa)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 30139780

Group type: EXPERIMENTAL
Intervention: Benralizumab 30 mg subcutaneously every 8 weeks (Q8W, first three doses every 4 weeks (Q4W))
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Benralizumab 30 mg subcutaneously every 4 weeks (Q4W)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28031704

Group type: EXPERIMENTAL
Intervention: CGA unit care
Number of subjects: 408

Group type: COMPARATOR
Intervention: Conventional acute medical care
Number of subjects: 408
Study: 26336957

Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin (10/20 mg)
Number of subjects: 1128

Group type: COMPARATOR
Intervention: atorvastatin (10 mg, 20 mg)
Number of subjects: 1128
Study: 24565342

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway Supreme(®) (LMAS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Endotracheal tube (ETT)
Number of subjects: 60
Study: 21779784

Group type: EXPERIMENTAL
Intervention: Aliskiren
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study: 18626722

Group type: EXPERIMENTAL
Intervention: Patients with serious mental illness (SMI)
Number of subjects: 24016

Group type: EXPERIMENTAL
Intervention: Patients with depression
Number of subjects: 24016

Group type: COMPARATOR
Intervention: Patients without SMI or depression (Control)
Number of subjects: 24016
Study: 16528523

Group type: EXPERIMENTAL
Intervention: Sulphonylurea drugs (SU group)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study: 12892606

Group type: EXPERIMENTAL
Intervention: SRK‐T formula
Number of subjects: 86

Group type: COMPARATOR
Intervention: SRK‐II formula
Number of subjects: 86

Group type: COMPARATOR
Intervention: Comparison of SRK‐T and SRK‐II
Number of subjects: 86

Group type: COMPARATOR
Intervention: K-readings at 39.00 D, 41.00 D, 45.00 D, or 47.00 D
Number of subjects: 86

Group type: COMPARATOR
Intervention: K-reading at 43.00 D
Number of subjects: 86

Group type: COMPARATOR
Intervention: Axial lengths
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Overall conclusion
Number of subjects: 86
Study: 11155900

Group type: EXPERIMENTAL
Intervention: Protease inhibitor (PI) therapy
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Second PI regimen after treatment failure
Number of subjects: 70
Study: 8646821

Group type: EXPERIMENTAL
Intervention: Intravenous ethanol (0.3 gm/kg)
Number of subjects: 12
Study: 1466216

Group type: EXPERIMENTAL
Intervention: 150 micrograms of epidural clonidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 300 micrograms of epidural clonidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: 10 mg of parenteral morphine
Number of subjects: 0
Study: 30679379

Group type: EXPERIMENTAL
Intervention: theory‐based, culturally tailored video
Number of subjects: 215

Group type: COMPARATOR
Intervention: usual‐care mainstream video
Number of subjects: 215
Study: 29562556

Group type: EXPERIMENTAL
Intervention: Progressive Resistance Training (PRT) of the lower extremities
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Balance and Motor Control Training (BMCT) that challenges gait function
Number of subjects: 90

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 90
Study: 28007025

Group type: EXPERIMENTAL
Intervention: XELIRI with or without bevacizumab (7.5 mg/kg on day 1), repeated every 3 weeks
Number of subjects: 600

Group type: COMPARATOR
Intervention: FOLFIRI with or without bevacizumab (5 mg/kg on day 1), repeated every 2 weeks
Number of subjects: 600
Study: 24796937

Group type: EXPERIMENTAL
Intervention: Leukoreduced red blood cell (RBC) transfusion
Number of subjects: 84

Group type: COMPARATOR
Intervention: No transfusion (control group)
Number of subjects: 84
Study: 22705093

Group type: EXPERIMENTAL
Intervention: ISO+WS (50 g isomaltulose + 21 g whey/soy)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ISO+C (50 g isomaltulose + 21 g casein)
Number of subjects: 30

Group type: COMPARATOR
Intervention: ISO (50 g isomaltulose)
Number of subjects: 30
Study: 21444695

Group type: EXPERIMENTAL
Intervention: Daptomycin (8 mg/kg of body weight)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control subjects (standard-of-care antibiotic)
Number of subjects: 15
Study: 17924898

Group type: EXPERIMENTAL
Intervention: Airtraq
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: McCoy
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ILMA
Number of subjects: 30

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 30
Study: 16214624

Group type: EXPERIMENTAL
Intervention: Structured telephone call
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Attention-only telephone call
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150
Study: 12169147

Group type: EXPERIMENTAL
Intervention: 5-hydroxytryptophan (5-HT)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: L-tryptophan
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 10199444

Group type: EXPERIMENTAL
Intervention: Tropisetron 5 mg intravenously followed by oral therapy for 5 days
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Tropisetron 5 mg intravenously plus dexamethasone before cisplatin and twice daily thereafter
Number of subjects: 301

Group type: COMPARATOR
Intervention: High-dose metoclopramide (2 mg/kg) combined with clemastine, dexamethasone, and lorazepam
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Tropisetron 5 mg intravenously plus dexamethasone
Number of subjects: 301

Group type: COMPARATOR
Intervention: High-dose metoclopramide cocktail
Number of subjects: 301
Study: 8849290

Group type: EXPERIMENTAL
Intervention: CI 5-FU 450 mg/body/day + IVB LV 30 mg/body q wk (schedule A)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: CI 5-FU 200 mg/m2/day + IVB LV 20 mg/m2 q wk (schedule B)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Inpatient chemotherapy (5-FU + CDDP)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Oral UFT (400-600 mg/day) after chemotherapy
Number of subjects: 36
Study: 1980218

Group type: EXPERIMENTAL
Intervention: Flumazenil (10 ml, 0.1 mg/ml)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo (10 ml vehicle alone)
Number of subjects: 105
Study: 6768088

Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 8

Group type: COMPARATOR
Intervention: Methylphenidate
Number of subjects: 8
Study: 31889356

Group type: EXPERIMENTAL
Intervention: Group B (2018)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Group A (2017)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Group A (2017) non-trauma patients
Number of subjects: 1000
Study: 31465100

Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.5 mg/0.05 mL)
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Aflibercept (2.0 mg/0.05 mL)
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Bevacizumab (1.25 mg/0.05 mL)
Number of subjects: 463
Study: 28335413

Group type: EXPERIMENTAL
Intervention: Chitin Oligosaccharide (COS) 20 mg with half-dose antibiotics
Number of subjects: 312

Group type: COMPARATOR
Intervention: Control group (CG) - one-gram alternative antibiotics
Number of subjects: 312

Group type: COMPARATOR
Intervention: Placebo group (PG) - 20 mg placebo with half-dose antibiotics
Number of subjects: 312
Study: 26110441

Group type: COMPARATOR
Intervention: DTSNB (Distal Transsartorial Saphenous Nerve Block)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: ACSNB (Adductor Canal Saphenous Nerve Block)
Number of subjects: 120
Study: 25603664

Group type: EXPERIMENTAL
Intervention: Pipelle endometrial sampling
Number of subjects: 203

Group type: COMPARATOR
Intervention: Dilatation and curettage (D&C)
Number of subjects: 203
Study: 22225530

Group type: EXPERIMENTAL
Intervention: superelastic NiTi Begg
Number of subjects: 96

Group type: COMPARATOR
Intervention: superelastic NiTi PEA
Number of subjects: 96

Group type: COMPARATOR
Intervention: multistranded (coaxial) stainless steel Begg
Number of subjects: 96
Study: 19458139

Group type: EXPERIMENTAL
Intervention: GHRH
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: GHRP-2
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Testosterone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: l-arginine
Number of subjects: 24
Study: 17766659

Group type: EXPERIMENTAL
Intervention: Pegaspargase (Oncaspar) at a dose of 2,500 IU/m(2) administered i.m. on day 3 of the 4-week induction phase and on day 3 of each of two 8-week delayed intensification phases
Number of subjects: 118

Group type: COMPARATOR
Intervention: Native Escherichia coli asparaginase (Elspar) at a dose of 6,000 IU/m(2) administered i.m. three times weekly for nine doses during induction and for six doses during each delayed intensification phase
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Pegaspargase (Oncaspar)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Native Escherichia coli asparaginase (Elspar)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Both Pegaspargase and Native Escherichia coli asparaginase
Number of subjects: 118
Study: 15292333

Group type: EXPERIMENTAL
Intervention: Low-dose GH (1.7 microg/kg.d)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 11208838

Group type: COMPARATOR
Intervention: Adjuvant postoperative radiotherapy (Arm A)
Number of subjects: 488

Group type: COMPARATOR
Intervention: Radiotherapy plus concurrent chemotherapy (Arm B)
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Wildtype K-ras
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Mutant K-ras randomized to chemotherapy plus radiotherapy
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: p53 mutations and protein overexpression
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: K-ras mutations
Number of subjects: 488
Study: 9635312

Group type: EXPERIMENTAL
Intervention: Bur preparation with a 1/4-round bur in a low-speed handpiece and acid etching
Number of subjects: 72

Group type: COMPARATOR
Intervention: Conventional preparation (pumicing and acid etching with 37% phosphoric acid)
Number of subjects: 72

Group type: COMPARATOR
Intervention: High-speed microabrasion using 50 mu alpha alumina particles in a KCP 2000 machine
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Unfilled sealant
Number of subjects: 72

Group type: COMPARATOR
Intervention: Filled sealant
Number of subjects: 72
Study: 7842343

Group type: EXPERIMENTAL
Intervention: Ginsenoside in total added into the cardioplegic solution
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ginsenoside Rb added instead of Ginsenoside in total
Number of subjects: 30

Group type: COMPARATOR
Intervention: No Ginsenoside used (Control group)
Number of subjects: 30
Study: 3123539

Group type: EXPERIMENTAL
Intervention: Oral cromolyn sodium (up to 40 mg/kg/day for 1 week)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31264770

Group type: EXPERIMENTAL
Intervention: Unilateral strength training with mirror therapy (MST)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Unilateral strength training (ST)
Number of subjects: 31
Study: 27914243

Group type: EXPERIMENTAL
Intervention: Bevacizumab-containing neoadjuvant therapy (BCP)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Carboplatin-paclitaxel (CP)
Number of subjects: 95
Study: 25892379

Group type: EXPERIMENTAL
Intervention: Sen Sib (SS) massage
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ratchsamnak (RS) massage
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Chaloeysak (CS) massage
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no massage)
Number of subjects: 30
Study: 24013512

Group type: EXPERIMENTAL
Intervention: 5 × 5 Gy irradiation followed by oxaliplatin-based chemotherapy
Number of subjects: 40
Study: 20861405

Group type: EXPERIMENTAL
Intervention: 250 units of vitamin D3 per day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 500 units of vitamin D3 per day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (not explicitly defined, but implied as no supplementation)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sun exposure
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: UVB exposure
Number of subjects: 40
Study: 19663688

Group type: EXPERIMENTAL
Intervention: DPSGC formulation A (25 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: DPSGC formulation B (25 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Liquid diclofenac formulation (1 mL, 25 mg)
Number of subjects: 24
Study: 17942039

Group type: EXPERIMENTAL
Intervention: Tonsilloplasty
Number of subjects: 30

Group type: COMPARATOR
Intervention: Tonsillectomy
Number of subjects: 30
Study: 15896757

Group type: EXPERIMENTAL
Intervention: Fluad (containing the MF59 adjuvant)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Agrippal (no adjuvant added)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (not vaccinated)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 58
Study: 11889461

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg, Tetracycline 500 mg, Furazolidone 200 mg (OTF group)
Number of subjects: 111
Study: 9640567

Group type: EXPERIMENTAL
Intervention: PSX group (n=23)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (n=23)
Number of subjects: 46
Study: 8135389

Group type: COMPARATOR
Intervention: Naloxone (5 micrograms/kg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Methylnaltrexone (0.3 mg/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 2642790

Group type: EXPERIMENTAL
Intervention: Systemic antibiotic treatment combined with topical application of antibiotics in the wound at the time of wound closure
Number of subjects: 190

Group type: COMPARATOR
Intervention: Systemic antibiotic treatment alone
Number of subjects: 190
Study: 50611

Group type: EXPERIMENTAL
Intervention: SCHEDULE B: 2 sessions per day totalling 3,440 rads in 10‐11 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SCHEDULE C: 2 sessions per day totalling 3,568 rads in 10‐11 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: SCHEDULE A (control): conventional one treatment per day regimen totalling 3,760 rads in 22‐23 days
Number of subjects: 0
Study: 28624990

Group type: EXPERIMENTAL
Intervention: Nutrition education workshops (six sessions)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Brochures (control group)
Number of subjects: 59
Study: 27913971

Group type: EXPERIMENTAL
Intervention: Myofunctional therapy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combined myofunctional therapy with CPAP
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo myofunctional therapy
Number of subjects: 100
Study: 26849547

Group type: EXPERIMENTAL
Intervention: Greek folk dancing (experimental group)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 63
Study: 23061531

Group type: EXPERIMENTAL
Intervention: Intravenous bolus injection of 2.5 mg/kg of Cyclosporine-A (CsA) before TLT
Number of subjects: 101

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 101
Study: 21198740

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training during pregnancy
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (nontraining participants)
Number of subjects: 84
Study: 17611167

Group type: EXPERIMENTAL
Intervention: Intervention group (Safer Choices 2 program)
Number of subjects: 711

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 711
Study: 16604967

Group type: EXPERIMENTAL
Intervention: 50 ml of saline solution with 100 ml of contrast material (300 mgI/ml)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 50 ml of saline solution with 100 ml of contrast material (350 mgI/ml)
Number of subjects: 120

Group type: COMPARATOR
Intervention: 100 ml of contrast material (300 mgI/ml) only
Number of subjects: 120

Group type: COMPARATOR
Intervention: 100 ml of contrast material (350 mgI/ml) only
Number of subjects: 120
Study: 12611440

Group type: EXPERIMENTAL
Intervention: Active elbow flexion and extension
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Active elbow flexion
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Prolonged elbow extension (unweighted)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Prolonged elbow extension (weighted)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Across time
Number of subjects: 20
Study: 9873961

Group type: EXPERIMENTAL
Intervention: Propofol‐Propofol (P‐P)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Propofol‐Isoflurane (P‐I)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Propofol‐Desflurane (P‐D)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Spinal anesthesia (S)
Number of subjects: 100
Study: 12836710

Group type: EXPERIMENTAL
Intervention: Lisinopril 10 mg once daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 2116533

Group type: EXPERIMENTAL
Intervention: Peptide-based enteral diet (Reabilan HN)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Intact-protein enteral diet (Osmolite HN)
Number of subjects: 18
Study: 356593

Group type: EXPERIMENTAL
Intervention: 6-methylprednisolone
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Liver biopsy feasibility
Number of subjects: 27
Study: 30579500

Group type: EXPERIMENTAL
Intervention: Intervention for reducing cholesterol and cardiovascular risk
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 27036712

Group type: EXPERIMENTAL
Intervention: Weight training followed by speed training (weights speed)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Speed training followed by weight training (speed weights)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Speed training sessions
Number of subjects: 15

Group type: COMPARATOR
Intervention: Weight training sessions
Number of subjects: 15
Study: 25150116

Group type: EXPERIMENTAL
Intervention: Blueberry powder (BB), equivalent to 250 g berries daily for 6 weeks
Number of subjects: 25
Study: 22672772

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (sham treatment)
Number of subjects: 20
Study: 19470551

Group type: EXPERIMENTAL
Intervention: Real electro‐acupuncture (n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham electro‐acupuncture (n = 30)
Number of subjects: 60
Study: 17305635

Group type: EXPERIMENTAL
Intervention: Topical cyclosporin
Number of subjects: 13

Group type: COMPARATOR
Intervention: Triamcinolone acetonide 0.1%
Number of subjects: 13
Study: 15352148

Group type: EXPERIMENTAL
Intervention: Clinical pathway (CP) for dementia treatment
Number of subjects: 43

Group type: COMPARATOR
Intervention: Conventional medical practice (Control)
Number of subjects: 43
Study: 12402726

Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural analgesia (PCEA)
Number of subjects: 640

Group type: COMPARATOR
Intervention: Continuous epidural infusion (CEI)
Number of subjects: 640
Study: 9809932

Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg daily)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) (0.625 mg of conjugated estrogen and 2.5 mg of medroxyprogesterone acetate daily)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Combination of HRT and Simvastatin
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 8689742

Group type: EXPERIMENTAL
Intervention: Open flap/expanded polytetrafluoroethylene (e‐PTFE) membrane combination therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open flap therapy alone
Number of subjects: 0
Study: 2667523

Group type: EXPERIMENTAL
Intervention: Nisoldipine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 656253

Group type: EXPERIMENTAL
Intervention: Enflurane 1%
Number of subjects: 20

Group type: COMPARATOR
Intervention: Halothane 0.5%
Number of subjects: 20